Wikipedia

What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a singular regulator?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We explain the debate over Vertex Pharmaceuticals’ novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an epitaph for Aduhelm and the retirement of an FDA icon.

advertisement

For more on what we cover, here’s the news on Vertex; here’s more on Aduhelm; here’s the exit interview with Janet Woodcock; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

advertisement